Riskpilot← Back to searchSign inGet full accessFOSEN TERAPEUTISKE SENTER AS
ASActiveOrg 984040903Physiotherapy activities · NACE 8695Est. 20025 employees
Revenue 2024
NOK 6,8M
+20% vs 2023
EBITDA margin
12.3%
+18% vs 2023
Equity ratio
5.2%
Financial strength
Net profit 2024
NOK 75K
+451% vs 2023
| Revenue | NOK 6,8M | +20% |
| EBITDA | NOK 833K | +18% |
| Net profit | NOK 75K | +451% |
| Total assets | NOK 7M | -6% |
| Equity | NOK 366K | +26% |
| Employees | 5 | — |
Legal name
FOSEN TERAPEUTISKE SENTER AS
Org number
984040903
Legal form
Aksjeselskap
NACE code
8695 · Physiotherapy activities
Founded
12. januar 2002
Share capital
NOK 100 000
Employees
5 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og ett styremedlem i fellesskap.
Company purpose
Drive fysikalsbehandling og trening av pasienter.
Address
Phone
+4772526070
Email
fosents.as1@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 4 551 | 5 872 | 5 908 | 5 651 | 6 797 |
| Staff expenses | −2 769 | −4 026 | −3 812 | −3 870 | −4 795 |
| EBITDA | 256 | 523 | 930 | 708 | 833 |
| Depreciation & amort. | −368 | −392 | 188 | −308 | −309 |
| EBIT | −112 | 131 | 1 118 | 400 | 524 |
| Net financials | −260 | −223 | −312 | −427 | −428 |
| Profit before tax | −372 | −92 | 807 | −27 | 96 |
| Tax | −77 | −0 | 154 | −6 | 21 |
| Net profit | −295 | −92 | 653 | −21 | 75 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 5 608 | 7 366 | 7 419 | 7 509 | 7 030 |
| Equity | 323 | 231 | 672 | 291 | 366 |
| Long-term debt | 4 422 | 6 234 | 6 049 | 5 778 | 5 469 |
| Short-term debt | 862 | 901 | 697 | 1 440 | 1 195 |
| Total debt | 5 284 | 7 135 | 6 746 | 7 217 | 6 664 |
EBITDA margin
12.3%
This company
15.8%
Market median
-22% vs market
20202024
Equity ratio
5.2%
This company
38.2%
Market median
-86% vs market
20202024
Return on equity
20.4%
This company
18.4%
Market median
+11% vs market
20202024
Net profit margin
1.1%
This company
8.1%
Market median
-86% vs market
20202024
Asset turnover
0.97×
This company
1.12×
Market median
+13% vs market
20202024
Debt / equity
18.21×
This company
0.62×
Market median
-2837% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
TB Chief Executive Officer | Chief Executive Officer | 2002 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2008 | |
| Deputy Chairman | 2008 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of FOSEN TERAPEUTISKE SENTER AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Thomas Bjørnebo | Chief Executive Officer | 0 companies |
| Rune Bjerke | Chairman | 0 companies |
| Paul Andre Kovsand | Deputy Chairman | 0 companies |